Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Biopharma Informatic Inc

Neither a doctor nor a teaching hospital

Research payments

$18,254,565

686 payments

Through program year 2025, Biopharma Informatic Inc is reported as receiving $18,254,565 in research payments, across 686 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,220,760 73
2024 Research $3,207,916 64
2023 Research $3,213,914 94
2022 Research $1,855,653 80
2021 Research $2,110,908 101
2020 Research $808,175 82
2019 Research $837,239 192

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $15,187,098 273 payments
  2. Amgen Inc. $1,885,395 25 payments
  3. Regeneron Pharmaceuticals, Inc. $466,940 71 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $224,131 59 payments
  5. AbbVie, Inc. $66,981 14 payments
  6. GlaxoSmithKline, LLC. $57,294 19 payments
  7. Shire North American Group Inc $51,138 28 payments
  8. H. Lundbeck A S $46,578 8 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $46,489 5 payments
  10. Boehringer Ingelheim International GmbH $39,948 78 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $2,306,049 8 payments
  2. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $917,985 10 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $803,016 5 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $735,023 5 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $710,548 2 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $596,681 19 payments
  7. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $563,108 2 payments
  8. A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of Ly3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (Qwint-3) $526,094 4 payments
  9. A Study of Retatrutide (Ly3437943) Once Weekly in Participants Who Have Obesity Or Overweight and Osteoarthritis of the Knee (Triumph-4) $520,582 4 payments
  10. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $510,914 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record